Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin
Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Recent announcements, achievements, and development milestones from PARI's pharmaceutical partners utilizing eFlow® Technology.
Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin
Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled murepavadin
Avalyn Pharma Reports Update in Ongoing Idiopathic Pulmonary Fibrosis Trial
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options